These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32641110)

  • 21. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
    Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
    BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy.
    Sato Y; Hiramatsu K; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Ogata M; Kadota JI; Itoh H
    Chemotherapy; 2018; 63(1):29-34. PubMed ID: 29169153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
    Chang HJ; Hsu PC; Yang CC; Siu LK; Kuo AJ; Chia JH; Wu TL; Huang CT; Lee MH
    J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teicoplanin as an anti-methicillin resistant Staphylococcus aureus agent in infections of severely poisoned intensive care unit patients/ Tehran- Iran.
    Salimi A; Talaie H; Rezaie Hemami M; Mahdavinejad A; Barari BB; Razi P; Kamalbeik S
    Acta Biomed; 2014 Jan; 84(3):189-95. PubMed ID: 24458163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.
    Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
    Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y
    J Antimicrob Chemother; 2022 Mar; 77(4):869-879. PubMed ID: 35022752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of teicoplanin concentrations and safety analysis in neonates.
    Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
    Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model-based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non-complicated methicillin-resistant staphylococcus aureus infection.
    Zhang XS; Chen YL; Wang YZ; Chen C; Chen YJ; Xu FM; Dai Y; Shi DW; Lin GY; Yu XB; Xiang DZ; Zhang CH
    Br J Clin Pharmacol; 2024 Feb; 90(2):452-462. PubMed ID: 37749762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes.
    Lee CH; Tsai CY; Li CC; Chien CC; Liu JW
    J Antimicrob Chemother; 2015 Jan; 70(1):257-63. PubMed ID: 25190719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal teicoplanin dosage regimens for methicillin-resistant Staphylococcus aureus infections in endocarditis patients and renal failure patients.
    Li N; Zhu L; Xu G; Ge T; Qi F; Li M
    J Chemother; 2017 Dec; 29(6):358-364. PubMed ID: 28587526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective study of teicoplanin loading regimen that rapidly achieves target 15-30 μg/mL serum trough concentration.
    Kato H; Hamada Y; Hagihara M; Hirai J; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    J Infect Chemother; 2016 May; 22(5):308-13. PubMed ID: 26960579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety Analysis.
    Yamada T; Kubota T; Yonezawa M; Nishio H; Kanno S; Yano T; Kobayashi D; Egashira N; Takada H; Hara T; Masuda S
    Pediatr Infect Dis J; 2017 Apr; 36(4):398-400. PubMed ID: 27977550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of teicoplanin in the treatment of bloodstream infection caused by methicillin-resistant coagulase-negative staphylococci.
    Yamada K; Ueda T; Nakajima K; Ichiki K; Tsuchida T; Otani N; Takahashi Y; Ikeuchi H; Uchino M; Koshiba M; Takesue Y
    J Infect Chemother; 2020 May; 26(5):459-464. PubMed ID: 31870587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections.
    Zhou L; Gao Y; Cao W; Liu J; Guan H; Zhang H; Shi Y; Lv W; Cheng L
    Infect Drug Resist; 2018; 11():29-36. PubMed ID: 29379306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
    Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term Treatment of Teicoplanin for Methicillin-resistant Staphylococcus aureus Sternal Osteomyelitis with Renal Impairment: A Case of High Teicoplanin Trough Levels Maintained by Therapeutic Drug Monitoring.
    Shiohira H; Nakamatsu M; Kise Y; Higa F; Tateyama M; Hokama N; Kuniyoshi Y; Ueda S; Nakamura K; Fujita J
    Yakugaku Zasshi; 2016; 136(9):1313-7. PubMed ID: 27592834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-centre retrospective observational study comparing trough blood concentration and safety of teicoplanin formulations.
    Shinoda R; Shinoda Y; Ohashi K; Matsuoka T; Hirose T; Sugiyama T; Yoshimura T
    J Infect Chemother; 2019 Jul; 25(7):563-566. PubMed ID: 30929977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.